[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

What is the purpose of the study?

This study involves research for the purpose of seeing how effective REGN2222 is at reducing medical visits for RSV infection when it is administered intramuscularly (IM), by inserting a needle into the muscle.

Upstate Institutional Review Board (IRB) Number:

770394

Study/Protocol ID:

R2222-RSV-1332

Study Phase:

Phase III

Patient Age Group:

Children

Principal Investigator:

Joseph B Domachowske

Who can I contact for more information?

Name: Jodi Halczyn
Phone: 315-464-1992
Email: halczynj@upstate.edu

Return to Previous Page || Search Again

Top